A Randomized Trial of Combination Anastrozole plus Gefitinib and of Combination Fulvestrant plus Gefitinib in the Treatment of Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer

INTRODUCTION: EGFR signalling pathways appear involved in endocrine therapy resistance in breast cancer. This trial estimates the antitumor efficacy and toxicity of the EGFR tyrosine kinase inhibitor gefitinib in combination with anastrozole or fulvestrant in postmenopausal hormone receptor positive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Carlson, Robert W., O'eill, Anne, Vidaurre, Tatiana, Gomez, Henry L., Badve, Sunil S., Sledge, George W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587179/
https://ncbi.nlm.nih.gov/pubmed/22418699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-1997-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge